345-24-4

Basic information

• Product Name: 1-BROMO-2,4-DIFLUORO-5-NITROBENZENE
• Synonyms: BUTTPARK 89\07-60;AURORA KA-7912;5-BROMO-2,4-DIFLUORONITROBENZENE;1-BROMO-2,4-DIFLUORO-5-NITROBENZENE;2,4-Difluoro-5-nitrobroMobenzene;2,4-Difluoro-5-BroMonitrobenzene;5-Bromo-2,4-difluoronitrobenzene 98%;Benzene, 1-broMo-2,4-difluoro-5-nitro-
• CAS NO: 345-24-4
• Molecular Formula: C₆H₂BrF₂NO₂
• Molecular Weight: 237.99
• Product Categories: Halides;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 345-24-4.mol
• Article Data: 18

Chemical Properties

• Melting Point: 19°C(lit.)
• Boiling Point: 85°C 0,4mm
• Flash Point: 106.5ºC
• Appearance: /
• Density: 1.89 g/cm³
• Vapor Pressure: 0.0308mmHg at 25°C
• Refractive Index: 1.5580 to 1.5620
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-BROMO-2,4-DIFLUORO-5-NITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-2,4-DIFLUORO-5-NITROBENZENE(345-24-4)
• EPA Substance Registry System: 1-BROMO-2,4-DIFLUORO-5-NITROBENZENE(345-24-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 345-24-4(Hazardous Substances Data)

Usage

General Description

1-Bromo-2,4-difluoro-5-nitrobenzene is a chemical compound with the molecular formula C6H2BrF2NO2. It is a yellow crystalline solid that is used in the synthesis of various pharmaceuticals and agrochemicals. This chemical is considered hazardous, as it is toxic if ingested, inhaled or in contact with skin. It can cause irritation to the respiratory system and skin, and may lead to serious health effects if not handled properly. It is important to use appropriate safety measures and protective equipment when working with this compound.

InChI:InChI=1/C6H2BrF2NO2/c7-3-1-6(10(11)12)5(9)2-4(3)8/h1-2H

Upstream product

• 348-57-2 2,4-difluorobromobenzene 

Relevant articles and documents

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and stucture-activity relationships

The discovery of new antibacterial agents with novel mechanisms of action is necessary to overcome the problem of bacterial resistance that affects all currently used classes of antibiotics. Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically validated targets of the fluoroquinolone antibiotics which exert their antibacterial activity through inhibition of the catalytic subunits. Inhibition of these targets through interaction with their ATP sites has been less clinically successful. The discovery and characterization of a new class of low molecular weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presented. The benzimidazole ureas are dual targeting inhibitors of both enzymes and possess potent antibacterial activity against a wide spectrum of relevant pathogens responsible for hospital- and community-acquired infections. The discovery and optimization of this novel class of antibacterials by the use of structure-guided design, modeling, and structure-activity relationships are described. Data are presented for enzyme inhibition, antibacterial activity, and in vivo efficacy by oral and intravenous administration in two rodent infection models.

Amino substituted aryloxybenzylpiperidine derivatives

This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.